IR thematic call on alirocumab



Sanofi and Regeneron hosted an IR Thematic Conference Call for the financial community focusing on alirocumab during the American College of Cardiology Annual Meeting.

Alirocumab (SAR236553/ REGN727) is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) for the reduction of LDL-cholesterol. Alirocumab is currently being evaluated in a large Phase 3 program in patients with hypercholesterolemia.